The current management of MINOCA patients typically involves the administration of standard therapy for myocardial infarction with obstructive CAD, such as antiplatelet agents, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors [10,12,13,14]. Here, ACE is linked to coronary artery disorder.